• Our Services

    We offer best-in-class research and consulting services pertaining to the markets of all geographies. Our experienced team of business analysts and consultants has mastered fundamental and advanced market research in diverse industries.

  • Syndicated Research

    Syndicated research is the most cost-effective market research approach, which gives an analytical outlook of the competitive positioning, product positioning, and size estimation of the market at the micro level. Our off-the-shelf reports offer key market insights that industry stakeholders require to base their business strategy on. Our syndicated research services empower our clients to meet diverse market objectives.

  • Customized Research

    we also deliver customized research services to address specific needs of our clients. With a vast pool of adroit analysts who are proficient in market research, we take pride in tailoring our research services to meet our clients’ definite requirements and aid their business growth.

  • Consulting Services

    Businesses, today, need to adapt themselves to the changes that transpire in the market. Staying abreast of the market trends, therefore, becomes imperative for accomplishing business objectives.

  • Our Vision

    To be the most trusted partner in our clients' success endeavors

Showing posts with label Clinical Trials and Results. Show all posts
Showing posts with label Clinical Trials and Results. Show all posts

Systemic Lupus Erythematosus Therapeutics – Pipeline Analysis, Clinical Trials and Results, Patents

Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation of cartilage and blood vessels. Pain and swelling in joints, sensitivity to sun, unexplained fever, joints and muscle pain, mouth ulcers, swollen glands, and others are some common symptoms of the disease. Additionally, kidneys, lungs, heart, and others can also get affected by SLE. The diagnosis of SLE is little difficult as it requires multiple tests and constant analysis. Anticardiolipin antibody test, antinuclear antibody (ANA) test, blood chemistries, complete blood count (CBC), urinalysis, and the erythrocyte sedimentation rate (ESR) are some tests to diagnose the disease.


Companies that are developing therapeutics for SLE have shown positive clinical results in the various phases of drug development. For instance, in March 2018, Ablynx announced topline results of vobarilizumab phase II trials. Treatment-related serious adverse events were reported in 2.0% of all vobarilizumab treated patients as compared to 6.5% in patients administered with placebo. The percentage of patients experiencing a serious infection was also lower in the vobarilizumab arms compared to the placebo arm (2.8% versus 6.5%). Treatment-emergent adverse events that led to study drug discontinuation were reported in 12.4% of all vobarilizumab treated patients.

Pharmaceutical companies are tending to develop various strategies to enhance the therapeutic pipeline of SLE. For instance, Ablynx is developing vobarilizumab for the treatment of vobarilizumab with the help of its proprietary Nanobody technology.

Takeda Pharmaceutical Company Limited, Anthera Pharmaceuticals Inc., Genentech Inc., UCB Biopharma SPRL, Merck & Co. Inc., Ablynx, and GlaxoSmithKline plc are some of the prominent players for developing drugs and therapies for SLE.

Browse report overview with detailed TOC on Systemic Lupus Erythematosus Therapeutics – Pipeline Analysis, Patents, Designations, and Collaborations

Share:

Niemann-Pick Disease Type C NPC Therapeutics Pipeline Analysis, Clinical Trials and Results, Patents

 Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances when gets collected in the brain tissues, it affects neurologic and psychiatric function.


The disease shows its first signs in mild-to-late childhood with the insidious onset of ataxia, dementia, and vertical supranuclear gaze palsy (VSGP). The occurrence of NPC can be confirmed by biochemical testing. NPC can also be diagnosed by skin test, in order to assess how the cells, move and store cholesterol. Furthermore, testing for the cells’ ability to modify cholesterol (cholesterol esterification test) has also been used for diagnostic purpose. Recently, blood-based testing for biomarkers (oxysterols, lysosphingolipids, bile acid metabolites) and molecular gene sequencing of NPC1 and NPC2 have replaced these methods.

It has been observed that regulatory bodies are granting designations to the pipeline drugs, in order to pace up the development process of these drugs. For instance, IntraBio Inc.’s IB1001 was granted Rare Pediatric Disease Designation by the USFDA in April 2018 and Orphan Drug Designation by USFDA and EMA in February 2018 and April 2017, respectively. Similarly, Orphazyme A/S’s arimoclomol has been granted Orphan Drug Designation (in January 2015), Fast-Track Designation (in June 2016), and Rare Pediatric Disease Designation (in January 2018) by the USFDA.

Some of the key players involved in the development of NPC therapeutics are Orphazyme A/S, IntraBio Inc., CTD Holdings Inc., Mallinckrodt plc, SOM INNOVATION BIOTECH SL, Neurotrope Inc., Actelion Pharmaceuticals Ltd., Okklo Life Sciences BV, Amicus Therapeutics Inc., Oraxion Therapeutics Inc., and COI Pharmaceuticals Inc.

Browse report overview with detailed TOC on Niemann-Pick Disease Type C (NPC) Therapeutics - Pipeline Analysis , Clinical Trials and Results

Share:

Adrenoleukodystrophy (ALD) Therapeutics Pipeline Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape


Adrenoleukodystrophy (ALD) Therapeutics Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments published by Pharma Proff, ALD currently exhibits a proliferating pipeline with 10 therapeutic candidates.



ALD Pipeline Insights

ALD is a X-linked genetic disease which falls under the family of leukodystrophies disorder. The disease is monogenetically inherited from parents to offspring, with 100% penetrance in men and 65% in heterozygous women. It is a multi-system disorder which prominently affects both central and peripheral nervous system, resulting in blindness, seizures and hyperactivity.

Request to Get Free Sample Pages at:  
 

The pathophysiologic condition of disease includes the accumulation of saturated very long chain fatty acids (VLCFA) in serum and tissues of central nervous system, which is a major factor for immune system abnormality and demyelination of neurons. It mainly affects nervous system and adrenal glands and causes various adrenal and neurological problems, such as leg stiffness, muscles spasms and weakness, urinary problems, and sexual dysfunction.

Browse report overview with detailed TOC on "Adrenoleukodystrophy (ALD) Therapeutics Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at: https://www.pharmaproff.com/report/adrenoleukodystrophy

Insights into Pipeline Segments
According to the research, many drugs acting as a therapeutic against ALD are administered orally. It has been found that oral route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction.

It has been observed that regulatory bodies are granting designations to the drugs in ALD pipeline, in order to pace up the development process. For instance, bluebird bio Inc. ‘s drug candidate, Lenti-D, received Orphan Drug Designation by the USFDA and EMA in 2012; and Breakthrough Therapy Designation by the USFDA in 2018. Similarly, Minoryx Therapeutics S.L. drug, MIN-102, received Orphan Drug Designation by the USFDA in 2017.

Some of the key players involved in the development of ALD are Poxel SA, bluebird bio Inc., Minoryx Therapeutics SL, NeuroVia Inc., SOM Innovation Biotech SL, Viking Therapeutics Inc., Orpheris Inc., MedDay Pharmaceuticals, Applied Genetic Technologies Corporation (AGTC), and Neuralgene.

Share:

Acute Kidney Injury (AKI) Therapeutics Segmental Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape


According to a new research report “Acute Kidney Injury (AKI) Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, AKI therapeutics currently exhibits a proliferating pipeline of 39 therapeutic candidates. 

AKI or acute kidney failure is a common medical condition reported among hospitalized patients, especially those with multiple comorbid conditions. AKI can occur due to various reasons including decreased renal perfusion, and obstruction of the urinary collecting system. Dehydration, abdominal pain, rise in blood pressure, mild back pain, and vomiting are some of the symptoms associated with the disease.

According to the research findings, majority of pipeline drug candidates are being developed for intravenous route administration. The advantage with this administration includes entire administered dose reaches the systemic circulation immediately, which increases the bioavailability of drug. Administration of therapeutics for AKI through intravenous route has shown promising results in clinical studies.

Request to Get Free Sample Pages at:                                                                                                                                                    https://www.pharmaproff.com/request-sample/1253


In November 2018, Angion Biomedica Corp. and Sinovant Sciences HK Limited entered into a collaboration and license agreement for the development of ANG-3777 for the treatment of patients with delayed graft function (DGF) following kidney transplantation and AKI following open-heart surgery requiring cardiopulmonary bypass.

Similarly, in May 2016, A1M Pharma AB collaborated with CSL Behring LLC to investigate the potential of combination therapy of Alpha 1 Microglobulin (A1M) and plasma protein in patients suffering from pre-eclampsia and AKI. The endogenous protein A1M is expected to showcase several protective mechanisms in tissues.

Sentien Biotechnologies Inc., AM-Pharma B.V., and Quark Pharmaceuticals Inc., are some other major companies involved in the development of drug candidates for the treatment of AKI.


AKI Therapeutics Pipeline Analysis

By Phase
By Molecule Type
By Route of Administration
By Company

Share:

Profile

Popular Posts

APSense

Labels

Linkedin Profile

APSense

Business Network

Recent Posts

Research Pages